Robert F Cornell
Overview
Explore the profile of Robert F Cornell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tantawy M, Langaee T, Wang D, Rubinstein S, Cornell R, Lenihan D, et al.
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39063038
This study investigates the association between circulating microRNA (miRNA) expression and cardiovascular adverse events (CVAE) in multiple myeloma (MM) patients treated with a carfilzomib (CFZ)-based regimen. A cohort of 60...
2.
Shabnaz S, Nguyen T, Williams R, Rubinstein S, Garrett T, Tantawy M, et al.
Clin Transl Sci
. 2024 May;
17(5):e13828.
PMID: 38783568
As a treatment for relapsed or refractory multiple myeloma (MM), carfilzomib has been associated with a significant risk of cardiovascular adverse events (CVAE). The goals of our study were to...
3.
Costa L, Chhabra S, Medvedova E, Dholaria B, Schmidt T, Godby K, et al.
Lancet Haematol
. 2023 Sep;
10(11):e890-e901.
PMID: 37776872
Background: For patients with newly diagnosed multiple myeloma, reaching minimal residual disease (MRD) negativity after treatment is associated with improved outcomes; however, the use of MRD to modulate therapy remains...
4.
Silbermann R, Schmidt T, Bal S, Dhakal B, Dholaria B, Biltibo E, et al.
EJHaem
. 2023 Aug;
4(3):775-778.
PMID: 37601885
Quadruplet induction, autologous hematopoietic cell transplant (AHCT), and measurable residual disease (MRD) response-adapted consolidation yield an unprecedented depth of response in newly diagnosed multiple myeloma. Patients treated on MASTER (NCT03224507)...
5.
Tantawy M, Yang G, Algubelli R, DeAvila G, Rubinstein S, Cornell R, et al.
Front Cardiovasc Med
. 2023 Jul;
10:1181806.
PMID: 37408649
Background: Proteasome inhibitor Carfilzomib (CFZ) is effective in treating patients with refractory or relapsed multiple myeloma (MM) but has been associated with cardiovascular adverse events (CVAE) such as hypertension, cardiomyopathy,...
6.
Bal S, Dhakal B, Silbermann R, Schmidt T, Dholaria B, Giri S, et al.
Am J Hematol
. 2022 Jun;
97(9):1170-1177.
PMID: 35731911
The incremental impact of autologous hematopoietic cell transplantation (AHCT) on disease burden with quadruplet induction in newly diagnosed multiple myeloma (NDDM) can be reappraised with the serial assessment of minimal...
7.
Pan D, Kaufman J, Htut M, Agrawal M, Mazumder A, Cornell R, et al.
Cancer Med
. 2021 Dec;
11(2):358-370.
PMID: 34921527
Filanesib is a first-in-class kinesin spindle protein inhibitor which demonstrated safety and encouraging activity in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma in a preliminary analysis of dose-escalation...
8.
Costa L, Chhabra S, Medvedova E, Dholaria B, Schmidt T, Godby K, et al.
J Clin Oncol
. 2021 Dec;
40(25):2901-2912.
PMID: 34898239
Purpose: The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) by next-generation sequencing (NGS) to inform the use...
9.
Bal S, Malek E, Kansagra A, Usmani S, Vij R, Godby K, et al.
Leukemia
. 2021 Nov;
36(3):877-880.
PMID: 34802043
No abstract available.
10.
Cornell R, Bishop M, Kumar S, Giralt S, Nooka A, Larson S, et al.
Am J Cancer Res
. 2021 Jul;
11(6):3285-3293.
PMID: 34249462
Despite advances in treatment, most patients with multiple myeloma (MM) will relapse, and long-term survival remains poor. B-cell maturation antigen (BCMA) is an ideal therapeutic target as it is expressed...